Dyspnea Treatment Market 2026-2031 - Rising Prevalence of Respiratory and Cardiovascular Diseases to Drive Growth
Dublin, Aug. 20, 2026 (GLOBE NEWSWIRE) -- "Dyspnea Treatment - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)" has been added to ResearchAndMarkets.com's offering.
Dyspnea Treatment Market to Reach USD 10.14 Billion by 2031 as COPD and Post-COVID Breathlessness Drive Demand
The global dyspnea treatment market was valued at USD 7.02 billion in 2025 and is projected to increase from USD 7.46 billion in 2026 to USD 10.14 billion by 2031. The market is expected to register a compound annual growth rate of 6.32% during the 2026-2031 forecast period. Rising chronic obstructive pulmonary disease (COPD) prevalence, persistent post-COVID respiratory symptoms, wider adoption of home oxygen concentrators, and advances in inhaled therapies are supporting sustained market growth.
COPD and Post-COVID Respiratory Symptoms Increase Treatment Demand
The growing burden of COPD and chronic breathlessness following COVID-19 is expanding the number of patients requiring long-term dyspnea management. Post-COVID cough has been reported in 48.1% of patients experiencing dyspnea, creating additional demand for respiratory medicines, supplemental oxygen therapy, pulmonary rehabilitation, and symptom-management solutions.
Virtual pulmonary rehabilitation is also emerging as an important component of care. Programs involving COPD patients who require supplemental oxygen have demonstrated 99% safe engagement, supporting the use of technology-enabled rehabilitation outside conventional clinical facilities. This trend is particularly relevant as healthcare providers seek scalable ways to manage chronic respiratory disease while reducing hospital visits and emergency admissions.
Asia-Pacific faces a growing COPD burden among adults aged 15 to 49, partly associated with particulate pollution and other environmental risk factors. Meanwhile, the estimated global direct and indirect economic cost of COPD could reach USD 4.326 trillion between 2020 and 2050. These clinical and financial pressures are accelerating investment in accessible, cost-effective dyspnea treatment options.
Home Oxygen Concentrators Gain Momentum in Emerging Markets
Portable and solar-powered oxygen concentrators are gaining adoption in middle-income countries where piped oxygen infrastructure and cylinder distribution remain limited. Solar-powered systems can deliver oxygen at an incremental cost of approximately USD 20 per disability-adjusted life-year saved, highlighting their potential for hospitals operating with constrained resources.
Oxygen conservation technologies are also improving treatment efficiency. Clinical testing of the OXFO valve showed oxygen savings of 92.3% without reducing target saturation levels. In Kenya, Rwanda, and Ethiopia, coordinated oxygen ecosystem programs increased procurement volumes by as much as 220%, while achieving a cost of USD 7.34 per patient treated. Patient-controlled flow technologies have also demonstrated meaningful benefits, with the FlexO2 device increasing self-management scores from 14 to 92 points.
Infrastructure Costs Remain a Key Market Restraint
Despite strong demand, the high capital cost of advanced oxygen delivery systems continues to restrict adoption in low- and middle-income healthcare facilities. Sophisticated high-flow oxygen units can cost more than USD 50,000, placing them beyond the budgets of many resource-constrained hospitals. Pulse oximetry programs also face procurement, staff training, maintenance, and implementation challenges.
Although solar oxygen concentrators offer favorable long-term economics, initial financing remains a significant barrier. Lower-cost technologies, including neonatal continuous positive airway pressure devices with integrated oxygen monitoring priced below USD 200, could improve access. However, these products still require broader clinical validation and regulatory approval before widespread deployment.
Additional factors shaping the dyspnea treatment market include the introduction of once-daily triple-combination inhalers, artificial intelligence-enabled wearables designed to identify early respiratory deterioration, and regulatory inconsistencies that can delay combined drug-device launches.
Supplemental Oxygen Therapy Retains Market Leadership
Supplemental oxygen therapy accounted for 68.74% of global dyspnea treatment revenue in 2025, supported by established clinical protocols, reimbursement coverage, and sustained demand from patients with ambulatory or nocturnal hypoxemia. However, relaxation and fan therapy is projected to expand at a 5.98% CAGR as clinical studies demonstrate symptom relief and value-based care models encourage the adoption of non-pharmacological interventions.
Pharmaceutical development is increasingly focused on precision medicine, convenient dosing, and environmental sustainability. Corticosteroids and anticholinergic agents continue to play important roles, while emerging biologics such as depemokimab may provide twice-yearly dosing and potential disease-modifying benefits. Evidence supporting handheld fan therapy is also encouraging greater institutional acceptance of affordable symptom-management tools.
Regional Dyspnea Treatment Market Outlook
North America generated 37.66% of global market revenue in 2025. Growth is supported by established insurance coverage, extensive pulmonary rehabilitation networks, favorable reimbursement changes, and rapid regulatory clearance for innovative respiratory treatments. Improved payment parity for pulmonary rehabilitation services has encouraged virtual program adoption, while pharmaceutical copay caps are helping address treatment affordability.
Asia-Pacific is forecast to be the fastest-growing regional market, registering a 7.78% CAGR. Significant COPD underdiagnosis indicates substantial unmet demand, including in Japan, where only 8.4% of individuals with airflow obstruction receive a formal diagnosis. Investments in solar-powered concentrators, oxygen generation plants, respiratory therapy education, and hospital workforce development are expected to strengthen regional treatment capacity.
Europe is anticipated to record steady growth due to universal healthcare systems, evidence-based respiratory guidelines, and increasing adoption of validated interventions. Environmental regulations are also accelerating the transition toward inhalers with lower global warming potential. Latin America, Africa, and the Middle East remain smaller but strategically important markets, with solar concentrators and regional oxygen hubs helping healthcare systems overcome infrastructure limitations and improve access to dyspnea treatment.
Key Topics Covered:
1 Introduction
1.1 Study Assumptions & Market Definition
1.2 Scope of the Study
2 Research Methodology
3 Executive Summary
4 Market Landscape
4.1 Market Overview
4.2 Market Drivers
4.2.1 Accelerating Prevalence of COPD and Post-COVID Breathlessness
4.2.2 Rapid Uptake of Home Oxygen Concentrators in Middle-Income Countries
4.2.3 Pipeline Arrival of Once-Daily Triple-Combo Inhalers
4.2.4 AI-Enabled Early-Warning Wearables Reducing ER Dyspnea Admissions
4.2.5 Reimbursement Expansion for Remote Pulmonary Rehab
4.3 Market Restraints
4.3.1 High Capital Cost of High-Flow Oxygen Systems in LMIC Hospitals
4.3.2 Drug-Device Regulatory Mismatches Delaying Combo Launches
4.3.3 Low Clinician Adoption of Non-Pharma Dyspnea Scoring Tools
4.3.4 Patent Expiration Pressures on Established Therapies
4.4 Regulatory Landscape
4.5 Pipeline Analysis
4.6 Porter's Five Forces Analysis
4.6.1 Threat of New Entrants
4.6.2 Bargaining Power of Buyers
4.6.3 Bargaining Power of Suppliers
4.6.4 Threat of Substitute Products
4.6.5 Intensity of Competitive Rivalry
5 Market Size & Growth Forecasts (Value)
5.1 By Treatment Type
5.1.1 Therapy
5.1.1.1 Supplemental Oxygen Therapy
5.1.1.2 Relaxation / Fan Therapy
5.1.2 Drug Class
5.1.2.1 Antianxiety Agents
5.1.2.2 Antibiotics
5.1.2.3 Anticholinergic Agents
5.1.2.4 Corticosteroids
5.1.2.5 Others
5.2 By Route of Administration
5.2.1 Oral
5.2.2 Inhalation
5.2.3 Others
5.3 By End User
5.3.1 Hospitals
5.3.2 Home Care Settings
5.3.3 Specialty and Pulmonary Rehab Centers
5.3.4 Ambulatory Surgical Centers
5.4 By Geography
5.4.1 North America
5.4.1.1 United States
5.4.1.2 Canada
5.4.1.3 Mexico
5.4.2 Europe
5.4.2.1 Germany
5.4.2.2 United Kingdom
5.4.2.3 France
5.4.2.4 Italy
5.4.2.5 Spain
5.4.2.6 Rest of Europe
5.4.3 Asia-Pacific
5.4.3.1 China
5.4.3.2 Japan
5.4.3.3 India
5.4.3.4 Australia
5.4.3.5 South Korea
5.4.3.6 Rest of Asia-Pacific
5.4.4 Middle East and Africa
5.4.4.1 GCC
5.4.4.2 South Africa
5.4.4.3 Rest of Middle East and Africa
5.4.5 South America
5.4.5.1 Brazil
5.4.5.2 Argentina
5.4.5.3 Rest of South America
6 Competitive Landscape
6.1 Market Concentration
6.2 Market Share Analysis
6.3 Company Profiles (includes Global level Overview, Market level overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share for key companies, Products & Services, and Recent Developments)
6.3.1 GlaxoSmithKline plc
6.3.2 AstraZeneca plc
6.3.3 Novartis AG
6.3.4 Teva Pharmaceutical Industries Ltd.
6.3.5 Boehringer Ingelheim International GmbH
6.3.6 Pfizer Inc.
6.3.7 Viatris Inc. (Mylan N.V.)
6.3.8 Sun Pharmaceutical Industries Ltd.
6.3.9 Hikma Pharmaceuticals plc
6.3.10 Lupin Limited
6.3.11 Amneal Pharmaceuticals LLC
6.3.12 Lannett Company Inc.
6.3.13 Mayne Pharma Group Limited
6.3.14 Bausch Health Companies Inc.
7 Market Opportunities & Future Outlook
7.1 White-space & Unmet-Need Assessment
For more information about this report visit https://www.researchandmarkets.com/r/yvfur5
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.